 NEW YORK, July 21, 2021 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX, an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will hold a conference call for investors to discuss its abstract presented at the Alzheimers Association International Conference. The call will take place on Monday, July 26 th at 4:15pm ET and will be hosted by the Companys Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. 